RT Journal Article
SR Electronic
T1 Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5785
OP 5791
DO 10.21873/anticanres.15395
VO 41
IS 11
A1 TOMOFUMI NARUSE
A1 SOUICHI YANAMOTO
A1 MITSUNOBU OTSURU
A1 NOBUHIRO YAMAKAWA
A1 TADAAKI KIRITA
A1 YUKARI SHINTANI
A1 TATSUSHI MATSUMURA
A1 MASAYA OKURA
A1 MASASHI SASAKI
A1 YOSHIHIDE OTA
A1 SHIN-ICHI YAMADA
A1 HIROSHI KURITA
A1 MASAHIRO UMEDA
A1 JAPAN ORAL ONCOLOGY GROUP (JOOG)
YR 2021
UL http://ar.iiarjournals.org/content/41/11/5785.abstract
AB Background/Aim: This study was conducted to compare the efficacy and safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma (R/M OSCC). Patients and Methods: This multicenter retrospective study involved a chart review of the clinical records of R/M OSCC patients treated with wCmab-PTX in each institution between January 2013 and December 2017. Data were collected, and the efficacy, safety, and treatment outcomes were analyzed. Results: The best overall response and disease control rates were 48.4% and 61.3%, respectively. The median PFS and OS were 6 and 13 months, respectively. There was no significant difference in prognosis with or without previous platinum administration. The grade 3-4 adverse events were leukopenia (16.1%), followed by acne-like rash (12.9%), and neutropenia (9.7%). All adverse events, excluding more than grade 3 infusion reactions, were tolerable and manageable. Conclusion: wCmab-PTX may be considered as a treatment option for R/M patients with OSCC that is refractory to platinum-based chemotherapy, or progressive disease after receiving chemotherapy.